| Date |
Title |
|
| 05/20/19 |
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Azelastine
|
|
| 05/20/19 |
Akorn to Present at the RBC Capital Markets Healthcare Conference
LAKE FOREST, Ill. , May 20, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY .
|
|
| 05/07/19 |
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced
|
|
| 04/18/19 |
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Loteprednol
|
|
| 04/18/19 |
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
LAKE FOREST, Ill. , April 18, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Fluticasone
|
|
| 04/15/19 |
Akorn to Report First Quarter 2019 Financial Results and Host Conference Call
LAKE FOREST, Ill. , April 15, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Tuesday, May 7, 2019 outlining its first quarter 2019 financial results.
|
|
| 03/21/19 |
Akorn Names Erislandy (Dandy) Dorado-Boladeres as Executive Vice President of Global Quality
LAKE FOREST, Ill. , March 21, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (NASDAQ: AKRX), today announced that Dandy Dorado-Boladeres has been named as Executive Vice President of Global Quality, effective March 25, 2019. Mr. Dorado brings decades of pharmaceutical industry experience and expertise with
|
|
| 03/01/19 |
Akorn Comments on Favorable Court Order
LAKE FOREST, Ill. , March 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) announced today that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG to bring a fraud claim against Akorn. On February 20 , Fresenius filed a proposed amended counterclaim seeking to add a
|
|
| 02/28/19 |
Akorn Provides Fourth Quarter and Full Year 2018 Results
LAKE FOREST, Ill. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the year ended 2018. Fourth Quarter 2018 and Recent Business Highlights Net revenue was $153 million , a decline of $33
|
|
| 02/20/19 |
Akorn Comments on Fresenius’ Proposed Amended Claims
LAKE FOREST, Ill. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) today announced that it strongly contests Fresenius’ proposed amended claims filed earlier today. Akorn believes these claims are meritless and overreaching. Akorn denies the allegations and will vigorously defend
|
|
| 02/11/19 |
Akorn to Report Fourth Quarter and Full Year 2018 Results
LAKE FOREST, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Akorn , Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, February 28, 2019 outlining the fourth quarter and full year 2018 results.
|
|
| 01/28/19 |
Akorn Announces New Executive and Board Appointments
LAKE FOREST, Ill. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive Vice President, Global Operations reporting to Douglas Boothe , President &
|
|
| 01/09/19 |
Akorn Receives FDA Warning Letter
LAKE FOREST, Ill. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter, dated January 4 , from the U.S. Food and Drug Administration ( FDA ) related to an inspection of its Decatur, Illinois
|
|
| 01/08/19 |
Akorn Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LAKE FOREST, Ill. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ: AKRX), today announced that Akorn granted an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) pursuant to an employment arrangement with Akorn’s newly appointed President and Chief Executive Officer
|
|
|
